Astrazeneca Pharma launches Benralizumab (Fasenra) for asthma patients; Stock skyrockets 11%

Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.

from India Infoline News Service https://ift.tt/3n9qiA4